share_log

Chardan Capital Reiterates Buy on SAB Biotherapeutics, Maintains $3 Price Target

Benzinga ·  Jun 15, 2023 04:13

Chardan Capital analyst Keay Nakae reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $3 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment